EMEA-002360-PIP01-18-M02 - paediatric investigation plan

tirzepatide
PIPHuman

Key facts

Active substance
tirzepatide
Therapeutic area
Endocrinology-Gynaecology-Fertility-Metabolism
Decision number
P/0174/2022
PIP number
EMEA-002360-PIP01-18-M02
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of type II diabetes mellitus
Route(s) of administration
Subcutaneous use
Contact for public enquiries

Eli Lilly and Company Ltd
E-mail: eu_paediatric@lilly.com 
Phone: +44 1256315000

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date
Compliance check done
No

Decision

Share this page